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Abstract 
Objectives: Pancreatic cancer is a lethal disease, hard to diagnose and usually results in poor 
prognosis and high mortality. Developing an artificial intelligence (AI) algorithm to accurately 
and universally predict the early cancer risk of all kinds of pancreatic cancer is extremely 
important. We propose an ensemble AI algorithm to predict universally cancer risk of all kinds 
of pancreatic lesions with noncontrast CT. 
Methods: Our algorithm combines the radiomics method and a support tensor machine (STM) 
by the evidence reasoning (ER) technique to construct a binary classifier, called RadSTM-ER. 
RadSTM-ER takes advantage of the handcrafted features used in radiomics and learning 
features learned automatically by the STM from the CTs for presenting better characteristics of 
lesions. The patient cohort consisted of 135 patients with pathological diagnosis results where 
97 patients had malignant lesions. Twenty-seven patients were randomly selected as 
independent test samples, and the remaining patients were used in a 5-fold cross validation 
experiment to confirm the hyperparameters, select optimal handcrafted features and train the 
model. 
Results: RadSTM-ER achieved independent test results: an area under the receiver operating 
characteristic curve of 0.8951, an accuracy of 85.19%, a sensitivity of 88.89%, a specificity of 
77.78%, a positive predictive value of 88.89% and a negative predictive value of 77.78%. 
Conclusions: These results are better than the diagnostic performance of the five experimental 
radiologists, four conventional AI algorithms, which initially demonstrate the potential of 
noncontrast CT-based RadSTM-ER in cancer risk prediction for all kinds of pancreatic lesions. 
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I. Introduction 
Pancreatic cancer is a lethal disease with an incidence that increases yearly, and it is the fourth 
leading cause of cancer-related deaths worldwide (1). Surgery remains the only curative 
treatment for pancreatic cancer. However, its prognosis is extremely poor, with a 5-year survival 
rate of approximately 9% in the United States and 7.2% in China, which is the lowest among 
ten leading cancer types (2, 3). The deep anatomical location of the pancreas and the biological 
characteristics of pancreatic cancer make pancreatic cancer able to hide extremely well and 
difficult to diagnose. Most patients have local invasion and/or distant metastasis at the time of 
initial diagnosis (2), which seriously affects the prognosis of pancreatic cancer and results in 
high mortality. Therefore, developing an accurate diagnosis strategy as early as possible is 
extremely important for improving overall survival, which can benefit patients receiving radical 
surgery and other precise treatments in a timely manner. 
Artificial intelligence (AI) is considered capable of predicting the risk of many diseases, as well 
as early pancreatic cancer. Such corresponding research has made great progress, especially 
that based on medical imaging (4). Gulshan et al. first developed a deep learning (DL)-based 
algorithm for the detection of diabetic retinopathy in retinal fundus photographs (5). A research 
group from Stanford University also demonstrated an automatic dermatologist-level classifier 
based on dermoscopic images for identifying different types of skin cancer (6). Titano et al. 
developed a weakly supervised algorithm with 37,236 head CTs for the surveillance of acute 
neurologic events (7). Luo et al. developed a real-time AI algorithm for the detection of upper 
gastrointestinal cancer by endoscopy (8). There is still much successful research on AI in 
medical applications (9), such as polyp detection in the colon during colonoscopy (10) and 
prediction of cardiovascular risk factors (11). Most of these studies were modeled based on DL, 
which requires a large dataset with more than ten thousand cases for training many parameters 
in DL architectures. Currently, for some clinical problems, such as pancreatic cancer, obtaining 
such a large dataset is still challenging for the following reasons: (1) the available data from 
one medical center are limited because of its relatively low incidence; (2) data collection from 
multiple centers is still hard because the data standardization and sharing problems from 
different medical centers is still challenging. Therefore, AI algorithm research on smaller 
datasets is very important and necessary for pancreatic cancer. 
AI research in pancreatic cancer has also attracted the attention of many researchers in recent 
decades, such as malignancy prediction of intraductal papillary mucinous neoplasms (IPMNs) 
based on quantitative imaging (12) and deep learning (13), computer-aided diagnosis of 
pancreatic serous cystic neoplasms (PSCNs) based on radiomics methods (14), prediction of 
the tumor grade based on CT features and texture analysis (15), outcome prediction of 
stereotactic body radiation therapy (SBRT) based on radiomics signatures (16), prediction of 
the success of chemotherapy for unresectable pancreatic cancer based on texture analysis (17) 
(18) (19), survival prediction based on CT texture analysis (20) and clinical parameters of SEER 
database (21). However, the research attention on pancreatic cancer is still relatively low. 
Moreover, most of these studies on the diagnosis or malignancy prediction of pancreatic lesions 
focused on only one subtype of pancreatic cancer, such as IPMNs (12) (13) and PSCNs (14). 
One universal AI-aided diagnosis algorithm for all kinds of pancreatic cancer would better 
satisfy the clinical requirements. Additionally, it would be better to build a model based on a 
larger dataset with all kinds of data than a model for one subtype. Moreover, there is similarity 
among all malignant lesions that can be learned with machine learning techniques. Therefore, 
constructing a universal AI-based diagnosis algorithm for pancreatic cancer has great clinical 
and technical significance. 
The conventional radiomics method with handcrafted features as input has achieved good 
performance in many medical AI studies (22), especially for tasks with smaller datasets (23, 24) 
(14). The handcrafted features are predefined by specialists for the special medical task before 
training the models. However, they are also thought to not reflect the natural disease 
characteristics (25). Some non-deep machine learning methods can automatically learn natural 
features from original data, such as support tensor machine (STM), which also have good 
performance in smaller datasets (26). As an excellent machine learning method for 
automatically learning features, STM could complement conventional radiomics methods 
based on handcrafted features. Instead, a radiomics-based algorithm with handcrafted features 
could also complement an STM-based algorithm. Therefore, combining both methods to 
construct an ensemble AI algorithm could improve the diagnostic performance for pancreatic 
cancer. 
In particular, for effectively and universally predicting the cancer risk of all kinds of pancreatic 
lesions, we propose an ensemble AI algorithm using a binary classification method with 
noncontrast CT. This ensemble AI algorithm combines the conventional radiomics method and 
the STM method based on the evidence reasoning (ER) technique to construct a binary classifier, 
called RadSTM-ER. In other words, RadSTM-ER fuses the handcrafted features used in 
radiomics and learning natural features learned by the STM and can take advantage of both 
features for presenting better characteristics of lesions. 
II. Materials 
2.1. Patient cohort 
This retrospective study was performed on 194 patients who underwent noncontrast CT scans 
for initial diagnosis before various treatments and pathological confirmation in the Department 
of Hepatobiliary Surgery II, Zhujiang Hospital, Southern Medical University, from January 
2010 to May 2019. As the gold standard, the diagnostic results with pathology were required to 
distinguish the benign lesions and malignant lesions for each patient. After removing some 
cases for missing pathology results, 135 patients were included in this study; 98 patients were 
diagnosed with malignant lesions and the remaining patients were diagnosed with benign 
lesions. For all 135 patients, the following detailed characteristics were evaluated: age at the 
time of treatment, sex, clinical symptoms (including history of pancreatitis), lesion location, 
imaging findings (including the lesion size and main pancreatic duct [MPD] diameter), 
pretreatment laboratory values (including carcinoembryonic antigen [CEA], and carbohydrate 
antigen 19-9 [CA19-9]), family history of pancreatic cancer and whether it was an unexpected 
discovery or not. For some patients, serum amylase (AMY) and blood lipase (LIP) before 
treatment were also examined. This study was performed in accordance with the Declaration of 
Helsinki (27). 
2.2. CT procedure 
For all the patients, CT scans were performed using a Brilliance TM 64 CT or Brilliance TM 
ICT scanner (Philips Medical Systems Nederland B.V., Best, the Netherlands). The CT volume 
consisted of different numbers of slices of size 512 ×512 pixels, the same slice thicknesses and  
reconstruction intervals of 5 mm and different pixel spacings with sizes from 0.5449*0.5449 to 
0.9062*0.9062 (mm 2). 
2.3. Data preprocessing 
The region of interest (ROI) of each lesion was manually delineated slice by slice by one 
experimental radiologist, which was further confirmed and amended by another high-level 
radiologist with 15 years of experience. Subsequently, all 2D ROIs were stacked to 3D ROI for 
each patient. Because of the pixel spacing difference between different CT scan devices and the 
large slice thicknesses of 5 mm, the 3D spline interpolation method was performed to fix the 
imaging resolution to 2 mm*2 mm*2 mm for each lesion. 
2.4. Experimental setup 
As demonstrated in figure 1, we randomly selected 20% of cases (27 cases including 9 benign 
lesions and 18 malignant lesions) as the independent test subset. For another 80% (108) of cases 
consisting of 27 benign lesions and 81 malignant lesions, we employed the 5-fold cross 
validation method to select the optimal feature subset for the radiomics-based method and all 
hyperparameters in our ensemble algorithm. For one round of 5-fold cross validation 
experiments, one group of hyperparameters, selected feature subset and the area under the 
receiver operating characteristic (ROC) curve (AUC) were obtained. The best AUCs were used 
as the criteria to select the optimal feature subset and hyperparameters. Finally, the ensemble 
algorithm RadSTM-ER was trained based on all 108 cases with the selected optimal feature 
subset and hyperparameters, which was tested using the independent subset. 
The AUC, accuracy (ACC), sensitivity (SEN), specificity (SPE), positive predictive value (PPV) 
and negative predictive value (NPV) were used to evaluate the diagnostic performance. The 
diagnostic performance of four conventional AI methods including the VGG16-based deep 
learning algorithm, the pure radiomics-based classifier, the pure STM-based classifier and the 
ensemble algorithm with simple average (RadSTM-Ave), five experimental radiologists were 
compared with our ensemble algorithms. 
III. Methods 
3.1. The flow of the proposed ensemble algorithm 
The flow of our proposed ensemble AI algorithm is illustrated in figure 2. First, ROIs of the 
lesions were delineated manually. Second, we extracted the handcrafted features based on the 
3D lesion ROIs and constructed the radiomics-based classifier using a support vector machine 
(SVM) coupled with a forward sequential feature selection method (SFS). Third, we 
constructed 3D lesion imaging tensors and used an STM-based classifier to automatically learn 
the natural features (learning features) while performing the classification task. Finally, the 
reliable analysis-based evidence reasoning (RAbER) method was used to fuse the output scores 
(probabilities) of both classifiers to obtain the ensemble AI algorithm (RadSTM-ER). 
3.2. The extraction of handcrafted features 
To construct the conventional radiomics-based classifier for the ensemble algorithm, we first 
extracted 29 high-level handcrafted features (see table 1) consisting of geometric, intensity and 
texture features extracted from the interpolated 3D lesion ROIs, which have been successfully 
applied in multiple medical AI tasks (28) (23). 
3.3. The construction of the 3D tensors 
To construct the STM-based classifier, which is an important part of the RadSTM-ER fusion 
algorithm, 3D lesion tensors of the same size need to be constructed for all the lesions. We used 
the maximal size of all the lesion ROIs interpolated as the tensor size, which is 71*76*75. For 
each lesion, a tensor was constructed whose center contained the interpolated 3D ROI and 
whose periphery zeros were filled. The constructed tensors and their 2D patches in one slice for 
four cases consisting of two benign lesions and two malignant lesions are shown in figure 3. 
3.4. The radiomics-based classifier 
The conventional radiomics classifier proposed first by Gillies et al. (22) converts the images 
into mineable data for achieving a particular task, which generally includes three steps: high-
throughput extraction of predefined quantitative features, also called radiomics features or 
handcrafted features, feature selection from these predefined features because of the existing 
redundancy, and analysis for decision support. In this study, we used SVM coupled with SFS 
(SVM-SFS) to perform feature selection to obtain the optimal feature subset from the 29 
handcrafted features described in subsection 3.2, which were applied successfully in our 
previous works (29) (23). Subsequently, the selected optimal features were fed into the SVM 
to perform the classification and obtain the output scores. 
3.5. The STM-based classifier 
We used a kernelled STM (KSTM) (26) with the 3D lesion tensors constructed in subsection 
3.3 as input to learn automatically the lesion features, which are also called learning features. 
Subsequently, the learning features were fed into the SVM to perform the classification and 
obtain the output scores. 
3.6. The reliable classifier fusion strategy 
We used the reliable analysis based evidence reasoning (RAbER) method (30) (31) to fuse the 
radiomics-based classifier and the STM-based classifier and obtain the ensemble classification 
algorithm. This RAbER strategy uses the weight that reflects the relative importance of each 
fused classifier and the reliability of the output score of each classifier to recalculate the 
probability scores based on the output scores of both fused classifiers. 
3.7. Statistical analyses 
All statistical analyses were performed using SPSS version 23.0 (SPSS, Chicago, IL). Two-
tailed t-tests were used to analyze the significant differences between benign and malignant 
lesions for all the patient characteristics, and bivariate chi-square tests were used to test the 
significant differences of the ROCs between our ensemble AI algorithm and the other compared 
AI algorithms with a P-value <0.05 indicating statistical significance. Logistic regression was 
used to perform univariable and multivariable analyses. 
IV. Results 
4.1. Characteristics of patients 
The characteristics of the patients are shown in table 2. Ninety-seven patients (71.85%) were 
pathologically diagnosed with malignancy, which was more than the remaining 38 patients 
(28.15%) diagnosed with benign lesions. Of the patients with malignant lesions, 55 patients 
were male; of the patients with benign lesions, 17 patients were male, which indicated that the 
proportion of malignant lesions in males was higher than that in females. Eight patients with 
malignant lesions and four patients with benign lesions experienced pancreatitis. Most lesions 
were located at the pancreatic head, body or tail, and some were located across the head and 
body, body and tail, and even the head, body and tail. The median and range of CA19-9 and 
CEA for each patient and AMY and LIP for some patients were accounted for, which showed 
that all the medians for the patients with malignant lesions were larger than those in the patients 
with benign lesions. The medians of the lesion sizes and MPD diameter in the patients with 
malignant lesions are also larger than those in the patients with benign lesions. Five patients 
had a history of pancreatic cancer in their families, and four patients with benign lesions had a 
history of pancreatic cancer. Of all patients, five patients with malignant lesions and 12 patients 
with benign lesions were found unexpectedly. 
4.2. Diagnostic performance of our ensemble AI algorithm 
The detailed results are shown in table 3. Our proposed ensemble AI algorithm RadSTM-ER 
obtained prediction accuracy, sensitivity, specificity, positive predictive value, negative 
predictive value, and AUC values of 85.19%, 88.89%, 77.78%, 88.89%, 77.78%, and 0.8951, 
respectively. These results were better than those of the other four compared AI algorithms. Our 
model also outperformed the five subspecialty-trained China board-certified radiologists with 
accuracies of 77.78%, 70.37%, 74.07%, 74.07%, and 74.07% 
The ROC curves of five AI algorithms are shown in figure 4 (a), and P-values in the bivariate 
chi-square test between the ROC curves of our ensemble algorithm and the other four compared 
AI algorithms are shown in table 3, which also indicated that our ensemble algorithm was better 
than the four compared methods. The comparisons with the performance of the five radiologists 
is shown in figure 4(b), where the red curve is the ROC curve of our ensemble AI algorithm 
and the five colored circles indicate the diagnosis results of five radiologists. The black circle 
is located on the ROC curve, which indicates that the ensemble algorithm RadSTM-ER and the 
fourth radiologist have similar levels. The other four circles are to the right of and under the 
ROC curve, which indicates that the ensemble AI algorithm has a higher level than these 
radiologists. 
4.3. Univariable and multivariable analysis of the diagnostic performance 
The results of the univariable and multivariable analysis between the malignancy of pancreatic 
lesions and the patient characteristics, the diagnosis results of the 5th radiologist who had the 
best performance among all radiologists and the output scores of our ensemble AI algorithm 
are shown in table 4. In the univariable analyses, the lesion size (≥ 40 mm), the diagnosis 
results of the 5th radiologist and the diagnosis results of our ensemble AI algorithm had a 
significant relationship with the malignancy of the pancreatic lesions. These three associated 
parameters were further subjected to multivariable logistic regression, which showed that the 
output scores of our ensemble AI algorithm and diagnosis results of the 5th radiologist were the 
identified factors for the malignancy of pancreatic lesions, while our ensemble AI algorithm 
had a higher odds ratio of 511.46 (95% confidence interval: 226.10–2049.49, P=0.008). 
4.5. The selected features 
The radiomics-based classifier selected six optimal features (table 5), which consisted of three 
intensity features, two geometric features and a texture feature. The three intensity features are 
the maximum, minimum and standard deviation of intensity. The two geometric features are 
minor diameter and the eccentricity of the lesion. The texture feature is the homogeneity.  
V. Conclusions and discussions 
In this study, we predicted the universal cancer risk of all kinds of pancreatic lesions using an 
ensemble AI algorithm. This ensemble AI algorithm combined the radiomics method and an 
STM to construct a binary classifier using the reliable classifier fusion strategy-based evidence 
reasoning technique (RadSTM-ER). Thus, the ensemble AI algorithm took advantage of the 
handcrafted features and the natural learning features from STM of noncontrast CT. 
This study did not focus on one pancreatic lesion subtype, such as PSCNs or IPMNs; rather, it 
universally predicted the malignancy of all kinds of pancreatic lesions and achieved the test 
performance with a prediction accuracy of 85.19%, a sensitivity of 88.89%, a specificity of 
77.78%, a PPV of 88.89%, an NPV of 77.78%, and an AUC of 0.8951. These prediction results 
were better than the diagnostic performance of five experimental radiologists, four other AI 
algorithms (see table 3 and figure 4), which indicates the feasibility of the universal AI 
algorithm. 
Because of the weak visual performance of pancreatic disease in noncontrast CT in humans, 
most radiologists usually diagnose pancreatic disease by combining contrast CT or other 
clinical parameters. Thus, the diagnostic performance of radiologists based on noncontrast CT 
does not always achieve the expected result. The performance of our proposed ensemble 
algorithm achieves a better performance than the radiologists. However, the fusion algorithm 
combining further contrast CT, serum examination parameters, and symptom information needs 
to be studied further when the data are complete. 
In total, 135 patients were included in this study, comprising 38 patients with benign lesions 
and 97 patients with malignant lesions. For most medical problems solved by the binary 
classification method, the majority classes are usually positive classes (malignant cases) (23, 
26, 32). However, the majority class is the negative class (benign cases) in this work. Such an 
opposite phenomenon might be caused by the fact that most patients with a primary diagnosis 
in the Department of Hepatobiliary Surgery II usually have uncomfortable symptoms and thus 
have a higher probability of malignancy. 
Additionally, because of the small dataset size (135 cases), we combined the handcrafted 
feature-based radiomics method and the nondeep machine learning method STM, which can 
automatically learn natural features to construct the ensemble AI algorithm without considering 
deep learning, although it has much potential in many medical tasks. If more data from different 
medical centers and institutes are collected, deep learning should be included in the ensemble 
algorithm to achieve better performance. 
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 Figure 1. The workflow of the experimental setup. AUC: the area under the ROC curve, ACC: 
accuracy, SEN: sensitivity, SPE: specificity, PPV: positive predictive value, NPV: negative 
predictive value. 
 
Figure 2. The flow of our proposed ensemble AI algorithm RadSTM-ER. SVM: support vector 
machine; SVM-SFS: SVM coupled with the forward sequential feature selection method (SFS); 
KSTM: kernelled support tensor machine; RAbER: the reliable analysis-based evidence 
reasoning method 
 Figure 3. The constructed 3D lesion tensors (top row) and their corresponding 2D patches, 
including the lesion in one slice (bottom row): the left columns are the benign lesions, and the 
right columns are the malignant lesions. 
 
                    (a)                                   (b) 
Figure 3. (a) The ROC curves of the five compared algorithms for the independent test samples; 
(b) the test performance of our ensemble AI algorithm and the five radiologists. The ROC curve 
for ensemble AI algorithm (red line) and the radiologist’s performance (colored circles) for the 
diagnosis results with just noncontrast CT. 
Table 1. The radiomics features used in our fusion algorithms. 
Intensity features Geometric features Texture features 
Minimum Volume Energy 
Maximum Major diameter Entropy 
Mean Minor diameter Correlation 
Standard 
deviation 
Eccentricity Contrast 
Sum Elongation Texture variance 
Median Orientation Sum-Mean 
Skewness Bounding box volume Inertia 
Kurtosis Perimeter Cluster shade 
Variance  Cluster prominence 
  Homogeneity 
  Max probability 
    Inverse variance 
Table 2. Patient characteristics. 
Characteristics Benign (38) Malignant (97) P-value 
Age, yrs, median (range) 50 [18-68] 60 [26-85] <0.0001 
Male sex, n (%) 17 (44.74) 55 (56.70) <0.0001 
History of pancreatitis, n (%) 4 (10.53) 8 (8.42) 0.2391 
Lesion location, n (%) 
Head 
Body 
Tail 
Head/body 
Body/tail 
Head/body/tail 
 
17 (77.74) 
11 (28.95) 
18 (47.37) 
2  (5.26) 
7  (18.42) 
1  (2.63) 
 
66 (68.04) 
21 (21.65) 
29 (29.90) 
2  (2.06) 
15 (15.46) 
1  (1.03) 
-- 
Lesion size, mm, median (range) 22.02[6.83-60.97] 25.08 [6.86-99.61] 0.0254 
MPD diameter, mm, median (range) 2.10 [0.80-7] 2.60 [0.70-18] 0.0078 
CA 19-9, U/ml, median (range) 12 [0.50-716.10] 242.13 [0.50-486930] 0.3278 
CEA, ng/ml, median (range)  1.50 [0.20-64.50] 4.00 [0.30-1109] 0.1697 
Family history of PC, n (%) 4 (10.53) 5 (5.15) -- 
Unexpected discovery, n (%) 12 (31.58) 5 (5.15) -- 
Serum AMY, IU/L, median (range) 69.0 [45-126.40] 71.10 [20.80-415.50] 0.0241 
Serum LIP, IU/L, median (range) 44.6 [22.7-214.5] 78.3 [6-1118.7] 0.0018 
Note. MPD, main pancreatic duct; CEA, carcinoembryonic antigen; CA19-9, carbohydrate 
antigen 19-9; AMY, serum amylase; LIP, blood lipase 
Table 3. The test results predicted by our proposed ensemble algorithm, four compared AI 
algorithms, five radiologists and four factors with cutoff points reported in guidelines. 
Methods ACC 
(%) 
SEN 
(%) 
SPE 
(%) 
PPV 
(%) 
NPV 
(%) 
AUC P-value 
 
 
AI algorithms 
RadSTM-ER 85.19 88.89 77.78 88.89 77.78 0.8951 -- 
RadSTM-Ave 81.48 88.89 66.67 84.21 75.00 0.8457 <0.000 
Radiomics 77.78 77.78 77.78 77.78 83.33 0.7963 <0.000 
STM 81.48 94.44 55.56 80.95 63.64 0.8210 <0.000 
DL 62.96 66.67 55.56 75.00 45.45 0.6420 <0.000 
 
 
Radiologists 
Radiologist 1 77.78 88.89 55.56 80.00 71.43 -- -- 
Radiologist 2 70.37 72.22 66.67 81.25 54.55 -- -- 
Radiologist 3 74.07 83.33 55.56 78.95 62.50 -- -- 
Radiologist 4  74.07 66.67 88.89 92.31 57.14 -- -- 
Radiologist 5 74.07 77.78 66.67 82.35 60.00 -- -- 
 
 
 
Table 4. Univariable/multivariable logistic regression analysis of the relationship between 
malignancy of pancreatic lesions and other factors. 
 Univariable Multivariable 
OR (95% CI)        P-value OR (95% CI)        P-value 
Age (≥ 70 yrs) 1.03 [0.98-1.09]       0.262  
Sex (male) 2.00 [0.38-10.58]      0.415  
Pancreatitis (+) 2.29 [0.22-24.14]      0.492  
Lesion size (≥ 40 mm) 0.90 [0.82-1.00]       0.039 0.80 [0.58-1.09]       0.158 
MPD diameter (≥ 10 mm) 1.57 [0.90-2.76]       0.115  
CA 19-9 (≥ 38 U/mL) 1.00 [0.99-1.01]       0.209  
CEA (≥ 5.1 ng/mL) 1.68 [0.83-3.41]       0.150  
Family history (+)  0.21 [0.02-2.66]       0.226  
Radiologist 5 (+) 16.00 [1.61-159.31]    0.018 53.70 [10.35-81.94]    0.012 
RadSTM-ER (≥ 0.5) 396.05 [107.14-468.08] 0.006 511.46 [226.10-2049.49] 0.008 
Note. MPD, main pancreatic duct; CEA, carcinoembryonic antigen; CA19-9, carbohydrate 
antigen 19-9; AMY, serum amylase; LIP, blood lipase 
Table 5. The optimal features selected by the ensemble algorithm 
Intensity features  Geometric 
features  
Texture features  
Maximum 
Minimum 
Standard deviation 
Minor diameter 
Eccentricity 
 
Homogeneity 
 
 
 
 
